The sphingosine-1-phosphate derivative NHOBTD inhibits angiogenesis both in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 413, Issue 2, 2011, Pages 189-193

  Kim, Beom Seok ^a   Park, Hyomi ^a   Ko, Seung Hwan ^b   Lee, Won Koo ^c   Kwon, Ho Jeong ^a  

^a Yonsei University   (South Korea)

^b Seoul National University   (South Korea)

^c Sogang University   (South Korea)

Author keywords

Angiogenesis; HUVEC; Hypoxia inducible factor 1 alpha; NHOBTD; Sphingosine 1 phosphate

Indexed keywords

[N [3 HYDROXY 1 MORPHOLINO 4 (3 OCTYLPHENYL)BUTAN 2 YL]TETRADECANAMIDE]; ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHICK EMBRYO; CHORIOALLANTOIS; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYSOPHOSPHOLIPIDS; MORPHOLINES; MYRISTATES; NEOVASCULARIZATION, PHYSIOLOGIC; SPHINGOSINE; UMBILICAL CORD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053104331     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.055     Document Type: Article

References (25)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Bussolino F., Mantovani A., Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 1997, 22:251-265.
4. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 1995, 73:333-346.
5. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 14:242-248.
6. Carmeliet P. Blood vessel and nerves: common signals, pathways and diseases. Nat. Rev. Genet. 2003, 4:710-720.
7. Hanahan D., Forkman J. Pattern and emerging mechanisms of the angiogenic swith during tumorigenesis. Cell 1996, 86:353-364.
8. Lee J., Shim J.S., Jung S.A., Lee S.T., Kwon H.J. N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorg. Med. Chem. Lett. 2005, 3:181-183.
9. Jung H.J., Shim J.S., Lee H.B., Kim C.J., Kuwano T., Ono M., Kwon H.J. Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. Biochem. Biophys. Res. Commun. 2007, 9:353. 376-380.
10. Shim J.S., Lee H.S., Shin J., Kwon H.J. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett. 2004, 20:163-169.
11. Deplanque G., Harris A.L. Anti-angiogenic agents: clinical trial design and therapies in development. Eur. J. Cancer 2000, 36:1713-1724.
12. Zakarija A., Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 2005, 17:578-583.
13. Merrill A.H., Schmelz E.-M., Dillehay D.L., Spiegel S., Shayman J.A., Schroeder J.J., Riley R.T., Voss K.A., Wang E. Sphingolipids - the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 1997, 142:208-225.
14. An S., Goetzl E.J., Lee H. Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J. Cell Biochem. Suppl. 1998, 30-31:147-157.
15. Igarashi Y., Yatomi Y. Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles. Acta Biochim. Pol. 1998, 45:299-309.
16. Song Y.S., Kim S.H., Sa J.H., Jin C., Lim C.J., Park E.H. Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom Phellinus linteus. J. Ethnopharmacol. 2003, 88:113-116.
17. Lee O.H., Kim Y.M., Lee Y.M., Moon E.J., Lee D.J., Kim J.H., Kim K.W., Kwon Y.G. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 1999, 264:743-750.
18. Moscatelli D., Rifkin D.B. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta 1988, 948:67-85.
19. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., Kim K.W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 2002, 97:290-296.
20. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7:437-443.
21. Spiegel S., Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 2002, 19:25851-25854.
22. Sanna M.G., Wang S.K., Gonzalez-Cabrera P.J., Don A., Marsolais D., Matheu M.P., Wei S.H., Parker I., Jo E., Cheng W.C., Cahalan M.D., Wong C.H., Rosen H. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2006, 2:434-441.
23. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 2005, 108:308-319.
24. Ader I., Malavaud B., Cuvillier O. When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res. 2009, 69:3723-3726.
25. 1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. USA 2003, 100:10664-10669.